University of Brasilia Ginkgo biloba cisplatin otoprotection study

Completed randomized Phase 2 study evaluating Ginkgo biloba extract GBE761, 240 mg/day, as a potential protective agent against cisplatin-induced ototoxicity measured by distortion-product otoacoustic emissions.

Corrected from a generic supplement row to the completed University of Brasilia cisplatin otoprotection study. The evidence supports a historical institution-led study, not an active commercial Ginkgo biloba hearing-loss program.